Alexander Drilon MD
@alexdrilon
Followers
4K
Following
906
Statuses
171
Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center
New York
Joined October 2011
In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. @YoninaMG @AlexiaIasonos
Now online in @CD_AACR, a special commentary for #ASCO24: Optimus-Era Dose Finding for Rare Cancers - by @YoninaMG, Sean Devlin, @AlexiaIasonos, and @alexdrilon @MSKCancerCenter
2
2
22
Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible.
1
31
104
RT @Sandra_Misale: Two research technician positions are immediately available in my lab @HopkinsMedicine @hopkinskimmel. You will be worki…
0
29
0
Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations @Sandra_Misale!!
I have some news, I'm thrilled to announce that the Misale Lab will open in July at @hopkinskimmel @HopkinsMedicine! We will work on resistance to therapy in solid tumors and we are hiring. Join us in this journey! #newPI #LabLaunch #cancer #kras #targetedtherapies #WomenInSTEM
0
3
19
0
0
2
Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.
Just published: #SHP2 Inhibition Sensitizes Diverse Oncogene-addicted Solid Tumors to Re-treatment with Targeted Therapy by @alexdrilon S. Michael Rothenberg and colleagues @MSKCancerCenter @PfizerOncMed. #ASCO23
0
16
43
RT @Sandra_Misale: Out today in @CD_AACR our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blo…
0
46
0
Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to @NouraChoudhury @YoninaMG @NeilVasan and the many contributing authors!!
0
9
58
@FawziAbuRous Thanks! The medians for larotrecrinib DoR and PFS have not yet been reached. (Median follow up was quoted here instead)
1
0
0
RT @LukasDelasos: Aaaaand we're back!! 9 years really flew by since I was last here while working at #MSKCC; now as a #HOfellow @ClevelandC…
0
1
0
@LukasDelasos @ClevelandClinic So great to run into you, Luke. We are incredibly proud of your accomplishments!!
0
0
3
Excellent work from the Klebanoff lab on TCR development for an HLA-A*03:01 restricted public neoantigen generated in the context of a PIK3CA H1047L catalytic subunit hotspot mutation.
A high-throughput platform to find rare #Tcells that recognize shared cancer #neoantigens identifies TCRs specific for a conserved and therapeutically actionable epitope in mutant PIK3CA, a common driver oncogene @KlebanoffLab @MSKCancerCenter @parkerici
0
1
9
RETi resistance in lung, thyroid & other cancers can be complex. This paper includes insights into the serial kinetics of resistance acquisition, the potential emergence of RET wild type populations & the frequency of polyclonal resistance. Proud to be part of this team!
0
7
53
The first publication of larotrectinib in NTRK fusion+ lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world.
.@alexdrilon et al. report on first analysis of the efficacy & safety of larotrectinib in pts with TRK fusion–positive lung cancer from a registrational data set. ORR of 73% ub 15 evaluable pts w OS of 40.7 months. Larotrectinib was well tolerated.
7
54
204
RT @AliSchram: Quick recap of today's presentation of Zeno in heavily pretreated NRG1+ solid tumors. Efficacy observed across tumor types w…
0
35
0
RT @AliSchram: I’m honored to be among the #ConquerCancer Grant & Award Class of 2021 (CDA) and 2018 (YIA). Donors make these research oppo…
0
7
0
RT @RielyMD: Congratulations to @NouraChoudhury on her @ConquerCancerFd @ASCO Young Investigator Award. I'm lucky to co-mentor her with @He…
0
4
0
RT @RETpositive: RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET+ cancers. Through ou…
0
17
0
Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients.
3
20
97
RT @natasharekhtman: MET IHC is back from the dead! We wrote it off as a biomarker, but pl see latest study from our group lead by @alexdri…
0
20
0